Capital Markets Day
LiDCO Group Plc
("LiDCO" or the "Company")
Capital Markets Day
LiDCO (AIM: LID), the hemodynamic monitoring company, announces it will be holding a Capital Markets Day for all investors on Thursday 12 September 2019.
A presentation will be led by CEO Matt Sassone, who will provide an overview of the Company and where it is currently positioned, and will also feature presentations by:
· Tim Hall, Chief Financial Officer
Tim has been with LiDCO since March 2019 and brought with him extensive experience of finance leadership within the med-tech sector.
· Shane Doorish, Head of North America
Shane joined LiDCO in January 2017 bringing with him 19 years of experience in the healthcare sector having originally trained as a critical care nurse. This includes 12 years with Edwards Lifesciences, a major global provider of hemodynamic monitoring, where Shane held a number of sales and marketing positions.
· Dr Frederic Michard, MD, PhD, Visionary critical care Doctor
Dr Frederic is a Visionary critical care Doctor, who trained in Paris and Boston at MGH-Harvard Medical School. He is currently founder and Managing Director of MiCo, a consulting firm which specialises in medical e-nnovations and has a direct interest in hemodynamic monitoring having co-developed the Pulse Pressure Variation, a parameter now displayed on most bedside and hemodynamic monitors. Finally, Dr Frederic was previously Vice President, Global Medical Strategy at Edwards LifeSciences.
· Eric Mills, Head of Technology
Eric has been at LiDCO for over 15 years having overseen the transformation of the technology to its current non-invasive form. He has a wealth of expertise in the hemodynamic monitoring market.
The event will be held at finnCap, 60 New Broad Street, London, EC2M 1JJ at 11.00am for a 11.15am start. This will be followed by light refreshments and an opportunity to talk to the Board and senior management further.
The presentation will be available on the Company website shortly after the event, and no new material or trading information will be provided.
To register, please email [email protected] or telephone Walbrook PR on the number below.
For further information, please contact:
LiDCO Group Plc
Matt Sassone (CEO)
Tim Hall (CFO)
Tel: +44 (0)20 7749 1500
| || |
Tel: +44 (0)20 7600 1658
Geoff Nash / Hannah Boros (Corporate Finance)
Andrew Burdis (ECM)
Walbrook PR Ltd
Tel: 020 7933 8780 or [email protected]
Mob: 07980 541 893
Mob: 07584 391 303
About LiDCO Group Plc (www.lidco.com)
LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.
Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, originally developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.
LiDCOunity: a hemodynamic monitor that combines the full suite of LiDCO technology (non-invasive, minimally invasive and calibrated technologies) into one platform. Designed to have the flexibility to adapt to a patient's changing acuity, the product enables clinicians to seamlessly transition between non-invasive, minimally invasive and calibrated hemodynamic monitoring. Version 2 of this software is only available on a new slim widescreen monitor and includes the optional high usage program software in selected markets.
LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness.
LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:
· early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug
· quantification of hemodynamic response guidance on effective delivery of fluids to ensure the right amount at the right time
The software incorporated into LiDCOrapid allows the LiDCOrapid monitor to co-display Medtronic's level of consciousness parameter ('BISTM')* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This addresses a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors.
LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.
*BISTM and Bispectral Index are trademarks of Medtronic registered in the US and foreign countries.
**CNAPTM is a trademark of CNSystems Medizintechnik AG.
LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.
LiDCO Distribution Network:
LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.
LiDCO's headquarters are in London and its shares are traded on AIM.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Quick facts: LiDCO Group PLC
Market Cap: £11.35 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE